Huya Bioscience appoints Shawn Mu as VP business development for China

14 October 2015

Chinese pharma company Huya Bioscience International has expanded its senior management team by appointing Shawn Xiaojun Mu as vice president of business development for China.

Dr Mu brings more than 20 years of research in health care investment and spent more than 10 years in the USA with Aventis Pharma and KV Pharmaceutical. Most recently he was a founding partner of Excess Alliance Consulting in Shanghai, helping pharma and medical device companies to develop business plans and financial strategies.

Clement Gingras, Huya’s chief technology officer and chief operating officer for Asia, said: "Dr Shawn Mu joins the Huya team at a perfect time as our China and global business is advancing to an exciting and pivotal stage. Shawn's extensive experience in pharmaceutical business and research will help ensure sustainable progress in HUYA's strategic global development of innovative drugs originating from China."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK